Induction of broadly cross-reactive neutralizing antibodies is a excessive precedence for AIDS vaccine growth however one which has confirmed troublesome to be achieved. While most immunogens generate antibodies that neutralize a subset of T-cell-line-adapted strains of human immunodeficiency virus type 1 (HIV-1), none to this point have generated a potent, broadly cross-reactive response in opposition to major isolates of the virus.
Even small increments in immunogen enchancment resulting in will increase in neutralizing antibody titers and cross-neutralizing exercise would speed up vaccine growth; nonetheless, a scarcity of uniformity in goal strains utilized by totally different investigators to evaluate cross-neutralization has made the comparability of vaccine-induced antibody responses troublesome. Thus, there’s an pressing want to determine commonplace panels of HIV-1 reference strains for broad distribution.
To facilitate this, full-length gp160 genes have been cloned from acute and early subtype B infections and characterised for use as reference reagents to evaluate neutralizing antibodies in opposition to clade B HIV-1. Individual gp160 clones have been screened for infectivity as Env-pseudotyped viruses in a luciferase reporter gene assay in JC53-BL (TZM-bl) cells. Functional env clones have been sequenced and their neutralization phenotypes characterised through the use of soluble CD4, monoclonal antibodies, and serum samples from contaminated people and noninfected recipients of a recombinant gp120 vaccine.
Env clones from 12 R5 major HIV-1 isolates have been chosen that weren’t unusually delicate or immune to neutralization and comprised a large spectrum of genetic, antigenic, and geographic range. These reference reagents will facilitate proficiency testing and different validation efforts aimed toward bettering assay efficiency throughout laboratories and can be utilized for standardized assessments of vaccine-elicited neutralizing antibodies.
Wnt proteins are lipid-modified and can act as stem cell progress components.
Wnt signalling is concerned in quite a few occasions in animal growth, together with the proliferation of stem cells and the specification of the neural crest. Wnt proteins are probably essential reagents in increasing particular cell varieties, however in distinction to different developmental signalling molecules equivalent to hedgehog proteins and the bone morphogenetic proteins, Wnt proteins have by no means been remoted in an energetic type.
Although Wnt proteins are secreted from cells, secretion is often inefficient and earlier makes an attempt to characterize Wnt proteins have been hampered by their excessive diploma of insolubility. Here we have now remoted energetic Wnt molecules, together with the product of the mouse Wnt3a gene. By mass spectrometry, we discovered the proteins to be palmitoylated on a conserved cysteine.
Enzymatic elimination of the palmitate or site-directed and pure mutations of the modified cysteine end in loss of exercise, and point out that the lipid is essential for signalling. The purified Wnt3a protein induces self-renewal of haematopoietic stem cells, signifying its potential use in tissue engineering.
RGD and different recognition sequences for integrins.
Proteins that include the Arg-Gly-Asp (RGD) attachment web site, along with the integrins that function receptors for them, represent a serious recognition system for cell adhesion. The RGD sequence is the cell attachment web site of a big quantity of adhesive extracellular matrix, blood, and cell floor proteins, and almost half of the over 20 recognized integrins acknowledge this sequence of their adhesion protein ligands.
Some different integrins bind to associated sequences of their ligands. The integrin-binding exercise of adhesion proteins will be reproduced by quick artificial peptides containing the RGD sequence. Such peptides promote cell adhesion when insolubilized onto a floor, and inhibit it when offered to cells in answer. Reagents that bind selectively to just one or just a few of the RGD-directed integrins will be designed by cyclizing peptides with chosen sequences across the RGD and by synthesizing RGD mimics.
As the integrin-mediated cell attachment influences and regulates cell migration, progress, differentiation, and apoptosis, the RGD peptides and mimics can be utilized to probe integrin capabilities in numerous organic programs. Drug design primarily based on the RGD construction could present new therapies for ailments equivalent to thrombosis, osteoporosis, and most cancers.
Quantification of mRNA utilizing real-time reverse transcription PCR (RT-PCR): traits and issues.
The fluorescence-based real-time reverse transcription PCR (RT-PCR) is extensively used for the quantification of steady-state mRNA ranges and is a crucial device for fundamental analysis, molecular medication and biotechnology. Assays are straightforward to carry out, succesful of excessive throughput, and can mix excessive sensitivity with dependable specificity. The know-how is evolving quickly with the introduction of new enzymes, chemistries and instrumentation.
However, whereas real-time RT-PCR addresses many of the difficulties inherent in standard RT-PCR, it has turn out to be more and more clear that it engenders new issues that require pressing consideration. Therefore, along with offering a snapshot of the state-of-the-art in real-time RT-PCR, this overview has a further goal: it’ll describe and talk about critically some of the issues related to deciphering outcomes which can be numerical and lend themselves to statistical evaluation, but whose accuracy is considerably affected by reagent and operator variability.
Reagents that inhibit the ubiquitin-proteasome proteolytic pathway in cells haven’t been out there. Peptide aldehydes that inhibit main peptidase actions of the 20S and 26S proteasomes are proven to cut back the degradation of protein and ubiquitinated protein substrates by 26S particles.
Unlike inhibitors of lysosomal proteolysis, these compounds inhibit the degradation of not solely irregular and short-lived polypeptides but in addition long-lived proteins in intact cells. We used these brokers to check the significance of the proteasome in antigen presentation. When ovalbumin is launched into the cytosol of lymphoblasts, these inhibitors block the presentation on MHC class I molecules of an ovalbumin-derived peptide by stopping its proteolytic technology.
SRPX2 Peptide |
|||
| 5475P | ProSci | 0.05 mg | 164.75 EUR |
|
Description: (NT) SRPX2 peptide |
|||
SRPX2 antibody |
|||
| 70R-20529 | Fitzgerald | 50 ul | 435 EUR |
|
Description: Rabbit polyclonal SRPX2 antibody |
|||
HEK-293T Telomerase Over-Expressing Cell Pellet |
|||
| abx069991-1Pellet | Abbexa | 1 Pellet | 398 EUR |
Mouse Sushi repeat-containing protein SRPX2 (Srpx2) |
|||
| 1-CSB-BP819154MO | Cusabio |
|
|
|
Description: Recombinant Mouse Sushi repeat-containing protein SRPX2(Srpx2) expressed in Baculovirus |
|||
Mouse Sushi repeat-containing protein SRPX2 (Srpx2) |
|||
| 1-CSB-EP819154MO | Cusabio |
|
|
|
Description: Recombinant Mouse Sushi repeat-containing protein SRPX2(Srpx2) expressed in E.coli |
|||
SRPX2 cloning plasmid |
|||
| CSB-CL022690HU-10ug | Cusabio | 10ug | 502 EUR |
|
Description: A cloning plasmid for the SRPX2 gene. |
|||
Anti-SRPX2 antibody |
|||
| STJ117629 | St John's Laboratory | 100 µl | 277 EUR |
|
Description: This gene encodes a secreted protein that contains three sushi repeat motifs. The encoded protein may play a role in the development of speech and language centers in the brain. This protein may also be involved in angiogenesis. Mutations in this gene are the cause of bilateral perisylvian polymicrogyria, rolandic epilepsy, speech dyspraxia and mental retardation. |
|||
Anti-SRPX2 Antibody |
|||
| STJ503134 | St John's Laboratory | 100 µg | 476 EUR |
Polyclonal SRPX2 Antibody |
|||
| APR13540G | Leading Biology | 0.1 mg | 659 EUR |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human SRPX2 . This antibody is tested and proven to work in the following applications: |
|||
SRPX2 Polyclonal Antibody |
|||
| 28966-100ul | SAB | 100ul | 252 EUR |
SRPX2 Polyclonal Antibody |
|||
| 28966-50ul | SAB | 50ul | 187 EUR |
SRPX2 Rabbit pAb |
|||
| A15434-100ul | Abclonal | 100 ul | 308 EUR |
SRPX2 Rabbit pAb |
|||
| A15434-200ul | Abclonal | 200 ul | 459 EUR |
SRPX2 Rabbit pAb |
|||
| A15434-20ul | Abclonal | 20 ul | 183 EUR |
SRPX2 Rabbit pAb |
|||
| A15434-50ul | Abclonal | 50 ul | 223 EUR |
anti- SRPX2 antibody |
|||
| FNab08240 | FN Test | 100µg | 548.75 EUR |
|
Description: Antibody raised against SRPX2 |
|||
SRPX2 Blocking Peptide |
|||
| DF12480-BP | Affbiotech | 1mg | 195 EUR |
Anti-SRPX2 antibody |
|||
| PAab08240 | Lifescience Market | 100 ug | 386 EUR |
Beaucage reagent |
|||
| HY-100951 | MedChemExpress | 10mM/1mL | 126 EUR |
BOP reagent |
|||
| 5-02141 | CHI Scientific | 25g | Ask for price |
BOP reagent |
|||
| 5-02142 | CHI Scientific | 100g | Ask for price |
Bradford reagent |
|||
| BDE641 | Bio Basic | 100ml | 61.01 EUR |
BOP reagent |
|||
| A7015-100000 | ApexBio | 100 g | 200 EUR |
|
Description: A peptide coupling reagent. Can be used in the preparation of phenyl esters of amino acids which have been shown to be valuable as blocked derivatives of amino acids in the field of peptide synthesis. |
|||
BOP reagent |
|||
| A7015-25000 | ApexBio | 25 g | 113 EUR |
|
Description: A peptide coupling reagent. Can be used in the preparation of phenyl esters of amino acids which have been shown to be valuable as blocked derivatives of amino acids in the field of peptide synthesis. |
|||
Bluing Reagent |
|||
| BRT030 | ScyTek Laboratories | 30 ml | 60 EUR |
Bluing Reagent |
|||
| BRT125 | ScyTek Laboratories | 125 ml | 63 EUR |
Bluing Reagent |
|||
| BRT3800 | ScyTek Laboratories | 1 Gal. | 184 EUR |
Bluing Reagent |
|||
| BRT500 | ScyTek Laboratories | 500 ml | 76 EUR |
Bluing Reagent |
|||
| BRT999 | ScyTek Laboratories | 1000 ml | 88 EUR |
Chymase reagent |
|||
| 30C-CP1129 | Fitzgerald | 5 units | 2185 EUR |
|
Description: Purified native Human Chymase reagent |
|||
Traut's Reagent |
|||
| 2330-1000 | Biovision | 349 EUR | |
Traut's Reagent |
|||
| 2330-500 | Biovision | 207 EUR | |
MTS Reagent |
|||
| 2808-1000 | Biovision | 990 EUR | |
MTS Reagent |
|||
| 2808-250 | Biovision | 365 EUR | |
MTT Reagent |
|||
| 2809-1G | Biovision | 180 EUR | |
MTT Reagent |
|||
| 2809-5G | Biovision | 544 EUR | |
Mouse Sushi repeat- containing protein SRPX2, Srpx2 ELISA KIT |
|||
| ELI-53443m | Lifescience Market | 96 Tests | 865 EUR |
Bovine Sushi repeat- containing protein SRPX2, SRPX2 ELISA KIT |
|||
| ELI-18130b | Lifescience Market | 96 Tests | 928 EUR |
Human Sushi repeat- containing protein SRPX2, SRPX2 ELISA KIT |
|||
| ELI-29242h | Lifescience Market | 96 Tests | 824 EUR |
Sheep SRPX2 ELISA Kit |
|||
| ESS0181 | Abclonal | 96Tests | 521 EUR |
Rat SRPX2 ELISA Kit |
|||
| ERS0181 | Abclonal | 96Tests | 521 EUR |
Rabbit SRPX2 ELISA Kit |
|||
| ERTS0181 | Abclonal | 96Tests | 521 EUR |
Monkey SRPX2 ELISA Kit |
|||
| EMKS0181 | Abclonal | 96Tests | 521 EUR |
Mouse SRPX2 ELISA Kit |
|||
| EMS0181 | Abclonal | 96Tests | 521 EUR |
Porcine SRPX2 ELISA Kit |
|||
| EPS0181 | Abclonal | 96Tests | 521 EUR |
Goat SRPX2 ELISA Kit |
|||
| EGTS0181 | Abclonal | 96Tests | 521 EUR |
Human SRPX2 ELISA Kit |
|||
| EHS0181 | Abclonal | 96Tests | 521 EUR |
Bovine SRPX2 ELISA Kit |
|||
| EBS0181 | Abclonal | 96Tests | 521 EUR |
Chicken SRPX2 ELISA Kit |
|||
| ECKS0181 | Abclonal | 96Tests | 521 EUR |
Canine SRPX2 ELISA Kit |
|||
| ECS0181 | Abclonal | 96Tests | 521 EUR |
Anti-SRPX2 Antibody (Biotin) |
|||
| STJ503135 | St John's Laboratory | 100 µg | 586 EUR |
Anti-SRPX2 Antibody (FITC) |
|||
| STJ503136 | St John's Laboratory | 100 µg | 586 EUR |
Polyclonal SRPX2 Antibody (Internal) |
|||
| APR13542G | Leading Biology | 0.05mg | 484 EUR |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human SRPX2 (Internal). This antibody is tested and proven to work in the following applications: |
|||
Rat SRPX2 shRNA Plasmid |
|||
| 20-abx989971 | Abbexa |
|
|
Mouse SRPX2 shRNA Plasmid |
|||
| 20-abx976738 | Abbexa |
|
|
Human SRPX2 shRNA Plasmid |
|||
| 20-abx959053 | Abbexa |
|
|
SRPX2 Polyclonal Conjugated Antibody |
|||
| C28966 | SAB | 100ul | 397 EUR |
SRPX2 ELISA KIT|Human |
|||
| EF003243 | Lifescience Market | 96 Tests | 689 EUR |
SRPX2 Recombinant Protein (Human) |
|||
| RP030124 | ABM | 100 ug | Ask for price |
SRPX2 Recombinant Protein (Mouse) |
|||
| RP175466 | ABM | 100 ug | Ask for price |
SRPX2 Recombinant Protein (Mouse) |
|||
| RP175469 | ABM | 100 ug | Ask for price |
SRPX2 Recombinant Protein (Rat) |
|||
| RP231089 | ABM | 100 ug | Ask for price |
BCA Reagent, 16ML |
|||
| C144-16ML | Arbor Assays | 16ML | 163 EUR |
Dissociation Reagent, 1ML |
|||
| X017-1ML | Arbor Assays | 1ML | 109 EUR |
Dissociation Reagent, 25ML |
|||
| X017-25ML | Arbor Assays | 25ML | 258 EUR |
Dissociation Reagent, 5ML |
|||
| X017-5ML | Arbor Assays | 5ML | 122 EUR |
Dissociation Reagent, 1ML |
|||
| X058-1ML | Arbor Assays | 1ML | 73 EUR |
Dissociation Reagent, 5ML |
|||
| X058-5ML | Arbor Assays | 5ML | 109 EUR |
Biolipidure-1002-Reagent |
|||
| Biolipidure-1002-10 | Cusabio | 10mL | 196 EUR |
|
Description: The Biolipidure-1002-Reagent is a synthetic amphoteric polymer that can be substituted for BSA in tubidimetric immunoassays. Biolipidure-1002 is an excellent blocker and also enhances assay sensitivity. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
|||
HighGene transfection reagent |
|||
| RM09014 | Abclonal | 1000μl | 270 EUR |
LP4K Transfection Reagent |
|||
| LP4K | GenTarget | 1.0 ml / vial | 304 EUR |
|
Description: Lipid based transfection reagent for large plasmid and multiple plasmid transfection in both adhesive and suspenstion cell types. |
|||
n-Heptane Reagent |
|||
| HC5400 | Bio Basic | 1L | 79 EUR |
Tri-RNA Reagent |
|||
| FATRR-001 | Favorgen | 100ml | 236 EUR |
Tri-RNA Reagent |
|||
| FATRR-002 | Favorgen | 50ml | 176 EUR |
Tri-RNA Reagent |
|||
| FATRR-003 | Favorgen | 450ml | 645 EUR |
DTT (Cleland's reagent) |
|||
| DB0058 | Bio Basic | 5g | 84.8 EUR |
DTNB (Ellman's Reagent) |
|||
| DB0113 | Bio Basic | 5g | 97.85 EUR |
Ethyl acetate Reagent |
|||
| EC4600 | Bio Basic | 1L | 79 EUR |
TissueDigest Reagent, 20X |
|||
| T101 | Insitus Biotechnologies | 10ml | 210 EUR |
Convoy? Transfection Reagent |
|||
| 1110-1ml | ACTGene | 341 EUR | |
Griess Reagent Kit |
|||
| 30100 | Biotium | 1KIT | 149 EUR |
|
Description: Minimum order quantity: 1 unit of 1KIT |
|||
PhosphoBlocker Blocking Reagent |
|||
| AKR-103 | Cell Biolabs | 1L | 328 EUR |
|
Description: Most commercially available Western blot blockers, such as dry milk or serum, are sufficient to block unreactive sites on the membrane. However, they are not designed to preserve phosphoprotein antigens during blotting. Our PhosphoBLOCKER Blocking Reagent provides superior blocking by maximizing signal-to-noise ratio. The PhosphoBLOCKER reagent particluarly excels with very low levels of endogenous phopsphoproteins. |
|||
PhosphoBlocker Blocking Reagent |
|||
| AKR-104 | Cell Biolabs | 4L | 711 EUR |
|
Description: Most commercially available Western blot blockers, such as dry milk or serum, are sufficient to block unreactive sites on the membrane. However, they are not designed to preserve phosphoprotein antigens during blotting. Our PhosphoBLOCKER Blocking Reagent provides superior blocking by maximizing signal-to-noise ratio. The PhosphoBLOCKER reagent particluarly excels with very low levels of endogenous phopsphoproteins. |
|||
EL Transfection Reagent |
|||
| 20-abx098880 | Abbexa |
|
|
Mycoplasma Prevention Reagent |
|||
| 20-abx098886 | Abbexa |
|
|
Girard's reagent T |
|||
| 20-abx184099 | Abbexa |
|
|
FcR blocking Reagent |
|||
| 20-abx290024 | Abbexa |
|
|
Detection Reagent A |
|||
| abx296004-120ul | Abbexa | 120 ul | 321 EUR |
Mycoplasma Prevention Reagent |
|||
| 20-abx298005 | Abbexa |
|
|
Biolipidure-1002-Reagent |
|||
| Biolipidure-1002-100 | Biolipidure | 100mL | 1223 EUR |
|
Description: The Biolipidure-1002-Reagent is a synthetic amphoteric polymer that can be substituted for BSA in tubidimetric immunoassays. Biolipidure-1002 is an excellent blocker and also enhances assay sensitivity. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
|||
Biolipidure-103-Reagent |
|||
| Biolipidure-103-10 | Biolipidure | 10mL | 196 EUR |
|
Description: The Biolipidure-103-Reagent is a synthetic amphoteric polymer that can be substituted for BSA. It has been shown to enhance signals in rapid tests, western blots, and other similar immunochromatographic assays. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
|||
Biolipidure-103-Reagent |
|||
| Biolipidure-103-100 | Biolipidure | 100mL | 1223 EUR |
|
Description: The Biolipidure-103-Reagent is a synthetic amphoteric polymer that can be substituted for BSA. It has been shown to enhance signals in rapid tests, western blots, and other similar immunochromatographic assays. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
|||
Biolipidure-1201-Reagent |
|||
| Biolipidure-1201-10 | Biolipidure | 10mL | 196 EUR |
|
Description: The Biolipidure-1201 Reagent is a synthetic amphoteric polymer that can be substituted for BSA. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
|||
Biolipidure-1201-Reagent |
|||
| Biolipidure-1201-100 | Biolipidure | 100mL | 1223 EUR |
|
Description: The Biolipidure-1201 Reagent is a synthetic amphoteric polymer that can be substituted for BSA. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
|||
Biolipidure-1301-Reagent |
|||
| Biolipidure-1301-10 | Biolipidure | 10mL | 196 EUR |
|
Description: The Biolipidure-1301 Reagent is a synthetic amphoteric polymer that can be substituted for BSA. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
|||
Biolipidure-1301-Reagent |
|||
| Biolipidure-1301-100 | Biolipidure | 100mL | 1223 EUR |
|
Description: The Biolipidure-1301 Reagent is a synthetic amphoteric polymer that can be substituted for BSA. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
|||
Biolipidure-203-Reagent |
|||
| Biolipidure-203-10 | Biolipidure | 10mL | 196 EUR |
|
Description: The Biolipidure-203 Reagent is a synthetic amphoteric polymer that can be substituted for BSA. Biolipidure-203 has been shown to enhance signal strength by improving signal-to-noise in ELISAs, EIAs, and related immunoassays. It also functions as an effective blocker and stabilizer in these assays. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
|||
Biolipidure-203-Reagent |
|||
| Biolipidure-203-100 | Biolipidure | 100mL | 1223 EUR |
|
Description: The Biolipidure-203 Reagent is a synthetic amphoteric polymer that can be substituted for BSA. Biolipidure-203 has been shown to enhance signal strength by improving signal-to-noise in ELISAs, EIAs, and related immunoassays. It also functions as an effective blocker and stabilizer in these assays. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
|||
Biolipidure-206-Reagent |
|||
| Biolipidure-206-10 | Biolipidure | 10mL | 196 EUR |
|
Description: The Biolipidure-206 Reagent is a synthetic amphoteric polymer that can be substituted for BSA. Biolipidure-206 enhances signal strength, functions as an effective blocker, and stabilizes proteins and antibodies in ELISAs, EIAs, and related immunoassays. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
|||
Biolipidure-206-Reagent |
|||
| Biolipidure-206-100 | Biolipidure | 100mL | 1223 EUR |
|
Description: The Biolipidure-206 Reagent is a synthetic amphoteric polymer that can be substituted for BSA. Biolipidure-206 enhances signal strength, functions as an effective blocker, and stabilizes proteins and antibodies in ELISAs, EIAs, and related immunoassays. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
|||
Biolipidure-405-Reagent |
|||
| Biolipidure-405-10 | Biolipidure | 10mL | 196 EUR |
|
Description: The Biolipidure-405 Reagent is a synthetic anionic polymer that can be used to enhance immunochromatographic assays. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
|||
Biolipidure-405-Reagent |
|||
| Biolipidure-405-100 | Biolipidure | 100mL | 1223 EUR |
|
Description: The Biolipidure-405 Reagent is a synthetic anionic polymer that can be used to enhance immunochromatographic assays. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
|||
Biolipidure-502-Reagent |
|||
| Biolipidure-502-10 | Biolipidure | 10mL | 196 EUR |
|
Description: The Biolipidure-502 Reagent is a synthetic cationic polymer. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
|||
Biolipidure-502-Reagent |
|||
| Biolipidure-502-100 | Biolipidure | 100mL | 1223 EUR |
|
Description: The Biolipidure-502 Reagent is a synthetic cationic polymer. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
|||
Biolipidure-702-Reagent |
|||
| Biolipidure-702-10 | Biolipidure | 10mL | 196 EUR |
|
Description: The Biolipidure-702 Reagent is a synthetic amphoteric polymer. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
|||
Biolipidure-702-Reagent |
|||
| Biolipidure-702-100 | Biolipidure | 100mL | 1223 EUR |
|
Description: The Biolipidure-702 Reagent is a synthetic amphoteric polymer. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
|||
Biolipidure-802-Reagent |
|||
| Biolipidure-802-10 | Biolipidure | 10mL | 196 EUR |
|
Description: The Biolipidure-802 Reagent is a synthetic amphoteric polymer that can be substituted for BSA. Biolipidure-802 generally enhances signal strength, functions as an effective blocker, and stabilizes proteins and antibodies in ELISAs, EIAs, Rapid-test, and related immunoassays. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
|||
Biolipidure-802-Reagent |
|||
| Biolipidure-802-100 | Biolipidure | 100mL | 1223 EUR |
|
Description: The Biolipidure-802 Reagent is a synthetic amphoteric polymer that can be substituted for BSA. Biolipidure-802 generally enhances signal strength, functions as an effective blocker, and stabilizes proteins and antibodies in ELISAs, EIAs, Rapid-test, and related immunoassays. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
|||
Alcohol, Reagent (70%) |
|||
| EAS500 | ScyTek Laboratories | 500 ml | 79 EUR |
Alcohol, Reagent (70%) |
|||
| EAS999 | ScyTek Laboratories | 1000 ml | 101 EUR |
PureFection Transfection Reagent |
|||
| LV750A-1 | SBI | 1 ml | 359 EUR |
Biotin reagent (HRP) |
|||
| 65C-CE0202 | Fitzgerald | 5 mg | 244 EUR |
|
Description: HRP conjugated biotin labelling reagent |
|||
BSA (Reagent Grade) |
|||
| 30-AB79 | Fitzgerald | 1 kg | 1552 EUR |
|
Description: Reagent Grade Bovine Serum Albumin (99% pure) |
|||
BSA (Reagent Grade) |
|||
| 30-AB81 | Fitzgerald | 200 grams | 476 EUR |
|
Description: Reagent Grade Sulphydryl Blocked BSA (99% pure) |
|||
HAMA blocking reagent |
|||
| 85R-1001 | Fitzgerald | 1 gram | 1974 EUR |
|
Description: HAMA Blocking Reagent for use in immunoassays such as ELISA |
|||
HAMA blocking reagent |
|||
| 85R-1001P | Fitzgerald | 1 gram | 2190 EUR |
|
Description: HAMA Blocking Reagent for use in immunoassays such as ELISA |
|||
HAMA blocking reagent |
|||
| 85R-1003 | Fitzgerald | 1 gram | 1974 EUR |
|
Description: HAMA Blocking Reagent for use in immunoassays such as Rapid Tests |
|||
HAMA blocking reagent |
|||
| 85R-1014 | Fitzgerald | 50 mg | 192 EUR |
|
Description: HAMA blocking reagent for use in assays specific for clinical false positive samples |
|||
HAMA blocking reagent |
|||
| 85R-1025 | Fitzgerald | 50 mg | 192 EUR |
|
Description: HAMA blocking reagent for use in immunoassays |
|||
HAMA blocking reagent |
|||
| 85R-1026 | Fitzgerald | 50 mg | 192 EUR |
|
Description: HAMA blocking reagent for use in immunoassays |
|||
Specimen Preservation Reagent |
|||
| DA0970 | Daan Gene | 100 test/kit | Ask for price |
Bradford Dye Reagent |
|||
| 0209R | AthenaES | 100 ml | 131 EUR |
BODIPY-Acetylene Reagent |
|||
| 2594-1 | Biovision | 207 EUR | |
BODIPY-Acetylene Reagent |
|||
| 2594-5 | Biovision | 675 EUR | |
ExFect2000 Transfection Reagent |
|||
| T202-01 | Vazyme | 0.5 ml | 227 EUR |
ExFect2000 Transfection Reagent |
|||
| T202-02 | Vazyme | 1 ml | 316 EUR |
ExFect2000 Transfection Reagent |
|||
| T202-03 | Vazyme | 5 ml | 1052 EUR |
Lung Lysate |
|||
| 1402 | ProSci | 0.1 mg | 191 EUR |
|
Description: Lung tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Brain Lysate |
|||
| 1403 | ProSci | 0.1 mg | 191 EUR |
|
Description: Brain tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Liver Lysate |
|||
| 1404 | ProSci | 0.1 mg | 191 EUR |
|
Description: Liver tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Kidney Lysate |
|||
| 1405 | ProSci | 0.1 mg | 191 EUR |
|
Description: Kidney tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Spleen Lysate |
|||
| 1406 | ProSci | 0.1 mg | 191 EUR |
|
Description: Spleen tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Thymus Lysate |
|||
| 1409 | ProSci | 0.1 mg | 191 EUR |
|
Description: Thymus tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Bladder Lysate |
|||
| 1410 | ProSci | 0.1 mg | 191 EUR |
|
Description: Bladder tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Colon Lysate |
|||
| 1411 | ProSci | 0.1 mg | 191 EUR |
|
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Cerebellum Lysate |
|||
| 1412 | ProSci | 0.1 mg | 191 EUR |
|
Description: Cerebellum tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Cerebrum Lysate |
|||
| 1413 | ProSci | 0.1 mg | 191 EUR |
|
Description: Cerebrum tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Pancreas Lysate |
|||
| 1414 | ProSci | 0.1 mg | 191 EUR |
|
Description: Pancreas tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Stomach Lysate |
|||
| 1415 | ProSci | 0.1 mg | 191 EUR |
|
Description: Stomach tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Testis Lysate |
|||
| 1416 | ProSci | 0.1 mg | 191 EUR |
|
Description: Testis tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Adrenal Lysate |
|||
| 1417 | ProSci | 0.1 mg | 191 EUR |
|
Description: Adrenal tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Skin Lysate |
|||
| 1419 | ProSci | 0.1 mg | 191 EUR |
|
Description: Skin tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Eye Lysate |
|||
| 1420 | ProSci | 0.1 mg | 191 EUR |
|
Description: Eye tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Esophagus Lysate |
|||
| 1421 | ProSci | 0.1 mg | 191 EUR |
|
Description: Esophagus tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Trachea Lysate |
|||
| 1422 | ProSci | 0.1 mg | 191 EUR |
|
Description: Trachea tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Heart Lysate |
|||
| 1461 | ProSci | 0.1 mg | 191 EUR |
|
Description: Heart tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Lung Lysate |
|||
| 1462 | ProSci | 0.1 mg | 191 EUR |
|
Description: Lung tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Brain Lysate |
|||
| 1463 | ProSci | 0.1 mg | 191 EUR |
|
Description: Brain tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Liver Lysate |
|||
| 1464 | ProSci | 0.1 mg | 191 EUR |
|
Description: Liver tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Kidney Lysate |
|||
| 1465 | ProSci | 0.1 mg | 191 EUR |
|
Description: Kidney tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Spleen Lysate |
|||
| 1466 | ProSci | 0.1 mg | 191 EUR |
|
Description: Spleen tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Pancreas Lysate |
|||
| 1469 | ProSci | 0.1 mg | 191 EUR |
|
Description: Pancreas tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Adrenal Lysate |
|||
| 1470 | ProSci | 0.1 mg | 191 EUR |
|
Description: Adrenal tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Thymus Lysate |
|||
| 1471 | ProSci | 0.1 mg | 191 EUR |
|
Description: Thymus tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
Colon Lysate |
|||
| 1472 | ProSci | 0.1 mg | 191 EUR |
|
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
|||
By stopping peptide manufacturing from cell proteins, these inhibitors block the meeting of class I molecules. Therefore, the proteasome catalyzes the degradation of the overwhelming majority of cell proteins and generates most peptides offered on MHC class I molecules.